Management of Allergic Rhinitis (AR) begins with avoiding the exposure of the allergens combined with drug therapy. Some of the common pharmacotherapies include antihistamines, intranasal glucocorticoids, or cromolyn mast cell stabilizers [1]. Despite providing some substantial relief in AR symptoms, these drugs are associated with side effects. One of the second lines of treatments is immunotherapy, which includes systemic injection of allergens in escalating, clinically tolerable doses [2]. Altering the mode of antigen delivery by mixing allergens with topical formulations may prove to be beneficial in treating allergic rhinitis in patients who have tried or failed subcutaneous immunotherapy and may confer substantially less side effects when compared to systemic medications.Topical creams have been shown to transfer pharmacological compounds, such as ketamine, gabapentin, clonidine, and baclofen, through the skin to reach target organs [3,4]. The transdermal creams offer an advantage by reducing side effects such as upset stomach, and application in low blood flow areas and can offer higher doses with lower concentrations throughout the body.

In addition to providing the allergen to the target immune organs, such as subcutaneous and sublingual immunotherapy, the use of a topical cream can also add an advantage by addition of an immune modulator or adjuvant. Toll-like Receptor (TLR) agonists have been shown to enhance or suppress the activity of various cell types [5-7]. Some, such as TLR4 have been approved by the FDA. TLR7 agonist imiquimod in a 5% cream was approved in 1997 for a topical treatment of genital warts, keratosis, and basal cell carcinoma [8]. Toll-like receptor stimulus including TLR 7 are found to inhibit Th2 responses and therefore may have utility in treatment of allergic disease [9]. Therefore, it was hypothesized that the topical application of an allergen contained in a transdermal base cream would produce Anti-Ovalbumin (OVA) antibody production in mice. Inclusion of TLR agonist was studied to determine if potential immune modulation is possible, such as increases or decreases in the antibody response..

In this Research Topic collection we invite researchers to submit manuscripts along the following themes:

Manuscript contributions that deal with Allergy And Therapy, etc. Establishing sustainable special issues on: • Allergen Immunotherapy, • Eosinophilic Disorders and Allergic Disorders • Allergic Rhinosinusitis topics.

-               Interdisciplinary research, observational field studies, experiments or manipulations, meta-analyses, reviews or modeling approaches are also welcome.

Journal of Allergy And Therapy is now accepting submissions on this topic. A standard EDITORIAL TRACKING SYSTEM is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.longdom.org/submissions/allergy-therapy.html) or forwarded to the Editorial Office at manuscripts@longdom.org

Laura Gray
Journal Manager
Journal of Allergy And Therapy
Email: allergy@eclinicalsci.com